Healthcare trend — Disruption score: 7.8/10
A once-daily oral GLP-1 agonist achieving comparable weight loss to injectable therapies represents a fundamental shift in obesity treatment accessibility and market dynamics, potentially displacing injectable dominance like Ozempic/Wegovy.
Paradigm Shift detected
Commercially Viable
Loading…